VCN-01 moves toward Phase 2/3 retinoblastoma trial after Theriva completes study design
Theriva designs a Phase 2/3 VCN-01 retinoblastoma trial after early eye-preservation signals. See what the planned FDA meeting could change.
Pharma & Biotech
Pharma & Biotech
Theriva Biologics leverages FDA and EMA feedback to optimize VCN-01 pivotal trial
Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Explore trial design, dosing strategy, and risks.
Pharma & Biotech
What Theriva Biologics’ APAO 2026 presentation signals for intravitreal oncology treatments
Theriva’s APAO 2026 VCN-01 data reveals how viral synergy and local delivery could redefine pediatric eye cancer care.